mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for TDRD3
Gene summary
Basic gene Info.Gene symbolTDRD3
Gene nametudor domain containing 3
CytomapUCSC genome browser: 13q21.2
Type of geneprotein-coding
Descriptiontudor domain-containing protein 3
Modification date20141207
dbXrefs MIM : 614392
Ensembl : ENSG00000083544
HPRD : 11625
Vega : OTTHUMG00000017007
ProteinUniProt: Q9H7E2
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_TDRD3
BioGPS: 81550
PathwayNCI Pathway Interaction Database: TDRD3
Pathway Commons: TDRD3
ContextiHOP: TDRD3
ligand binding site mutation search in PubMed: TDRD3
UCL Cancer Institute: TDRD3
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:1903506regulation of nucleic acid-templated transcription21172665

Ligand binding site mutations for TDRD3
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for TDRD3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for TDRD3 from PDB

Differential gene expression and gene-gene network for TDRD3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of TDRD3 and the right PPI network was created from samples without mutations in the LBS of TDRD3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for TDRD3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for TDRD3
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of TDRD3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of TDRD3
Multiple alignments for Q9H7E2 in multiple species
LBSAA sequence# speciesSpecies
E568FALYWEDNKFY4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
E568LALYWEDNKFY2Danio rerio, Bos taurus
E568LALYWEDNKYY1Xenopus tropicalis
E598DYGNYEEVLLS5Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus
E598DYGNCEEVLLD1Danio rerio
E598DYGNYEEVLLE1Xenopus tropicalis
F591TAVVKFIDYGN2Homo sapiens, Bos taurus
F591TAVVKFSDYGN2Xenopus tropicalis, Gallus gallus
F591TAVVKFTDYGN2Mus musculus, Rattus norvegicus
F591TAVVVFSDYGN1Danio rerio
N596FIDYGNYEEVL2Homo sapiens, Bos taurus
N596FSDYGNYEEVL2Xenopus tropicalis, Gallus gallus
N596FTDYGNYEEVL2Mus musculus, Rattus norvegicus
N596FSDYGNCEEVL1Danio rerio
W567CFALYWEDNKF4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
W567CLALYWEDNKF2Danio rerio, Bos taurus
W567CLALYWEDNKY1Xenopus tropicalis
Y566ECFALYWEDNK4Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus
Y566ECLALYWEDNK2Xenopus tropicalis, Bos taurus
Y566QCLALYWEDNK1Danio rerio
Y573EDNKFYRAEVE5Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus
Y573EDNKFYRARID1Danio rerio
Y573EDNKYYRAEVE1Xenopus tropicalis
Y594VKFIDYGNYEE2Homo sapiens, Bos taurus
Y594VKFSDYGNYEE2Xenopus tropicalis, Gallus gallus
Y594VKFTDYGNYEE2Mus musculus, Rattus norvegicus
Y594VVFSDYGNCEE1Danio rerio

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas